Skip to main content
Premium Trial:

Request an Annual Quote

John Anson, Paul Kenny

Oxford Gene Technology has announced that it has appointed John Anson as CEO, who previously served as executive VP of research and development. He will be replacing Mike Evans, who has become a non-executive director of OGT's board 

In addition, OGT has appointed Paul Kenny as executive VP of regulatory and medical affairs. Kenny previously served as head of regulatory affairs at The Binding Site. 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.